ArticleContemporary clinical trials communications2020

Design and rationale of FLAVOUR: A phase IIa efficacy study of the 5-lipoxygenase activating protein antagonist AZD5718 in patients with recent myocardial infarction.

Eva Prescott et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.